Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cognitive ability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    299 result(s) found for: Cognitive ability. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-001850-13 Sponsor Protocol Number: GLP-1/MCI Start Date*: 2015-09-11
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia?
    Medical condition: Moderate cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003111-58 Sponsor Protocol Number: AD-4833/TOMM40_301 Start Date*: 2013-09-20
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024119-15 Sponsor Protocol Number: rs4680-tolcapona Start Date*: 2014-04-10
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680
    Medical condition: Esquizofrenia crónica controlada. (10 pacientes con el genotipo val/val y 10 pacientes con el genotipo met/met)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2018-003567-66 Sponsor Protocol Number: T817MAEU201 Start Date*: 2019-06-11
    Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd.
    Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer...
    Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    21.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003410-15 Sponsor Protocol Number: 6251 7976 Start Date*: 2005-11-21
    Sponsor Name:Neurology Unit
    Full Title: A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis.
    Medical condition: Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003209-92 Sponsor Protocol Number: EVP-6124-016 Start Date*: 2013-10-22
    Sponsor Name:Forum Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti...
    Medical condition: Cognitive impairment associated with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    18.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003208-10 Sponsor Protocol Number: EVP-6124-015 Start Date*: 2013-06-28
    Sponsor Name:Forum Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti...
    Medical condition: Cognitive impairment associated with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    18.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002277-22 Sponsor Protocol Number: AMYPAD-02 Start Date*: 2018-09-12
    Sponsor Name:Stichting VUmc
    Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001572-19 Sponsor Protocol Number: 14122A Start Date*: 2011-12-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD)
    Medical condition: -Cognitive dysfunction -Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10057668 Cognitive disorder PT
    14.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005915-13 Sponsor Protocol Number: TRx-014-002 Start Date*: 2006-07-12
    Sponsor Name:TauRx Therapeutics PTE Ltd
    Full Title: An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes
    Medical condition: Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potent...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012267 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003228-19 Sponsor Protocol Number: EVP-6124-017 Start Date*: 2014-02-26
    Sponsor Name:EnVivo Pharmaceuticals, Inc.
    Full Title: A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ...
    Medical condition: Cognitive impairment associated with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) GB (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004840-51 Sponsor Protocol Number: EIP19-NFD-401 Start Date*: 2019-06-26
    Sponsor Name:EIP Pharma, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)
    Medical condition: Early-Stage Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022085-26 Sponsor Protocol Number: rhLAMAN-03 Start Date*: 2010-10-05
    Sponsor Name:Zymenex A/S
    Full Title: A single center, randomized, open-label, multiple-dose study of the efficacy and long-term safety of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alph...
    Medical condition: Treatment of alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000979-18 Sponsor Protocol Number: AZ3100603 Start Date*: 2005-06-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with...
    Medical condition: Alzheimer’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002595-13 Sponsor Protocol Number: 18F-AV-45-A18 Start Date*: 2013-03-01
    Sponsor Name:AVID RADIOPHARMACEUTICALS, INC.
    Full Title: A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (1...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000258-64 Sponsor Protocol Number: D1449L00004 Start Date*: 2005-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Co...
    Medical condition: Schizophrenia is a chronic psychiatric disorder that often begins during adolescence or early adulthood. A major problem for patients with schizophrenia is a cognitive deficit compared to a control...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005780-16 Sponsor Protocol Number: 1042_OPBG_2016 Start Date*: 2019-04-10
    Sponsor Name:IRCCS Bambino Gesù Children's Hospital
    Full Title: A phase 2 controlled study with blinded outcome assessment on the efficacy of Bumetanide vs no drug treatment for cognitive improvement to rescue cognitive functions in children and adolescents wit...
    Medical condition: Down Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000492-17 Sponsor Protocol Number: NL39440.029.10 Start Date*: 2012-10-29
    Sponsor Name:Afdeling Klinische Neuropsychologie Vrije Universiteit Amsterdam
    Full Title: The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children with ADHD: A Randomised Placebo Controlled Trial
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002386-18 Sponsor Protocol Number: 11-185/CAIAC Start Date*: 2016-03-15
    Sponsor Name:RWTH Aachen Clinical Trials Center Aachen (CTC-A)
    Full Title: Network connectivity and inhibitory control under atomoxetin challenge - A pharamacological "resting state" and "inhibitory task" fMRI study in patients with ADHD
    Medical condition: Patients with Attention-Deficit/Hyperactivity Disorders (ADHD)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000468-95 Sponsor Protocol Number: AZ3106242 Start Date*: 2006-06-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's Disease
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) SK (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 17:57:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA